Project

HPV Vaccination Rates in the Transgender Male Population

Since 2011, in the United States, the human papillomavirus vaccine (HPV) has been recommended for transgender men through age 26. This is a grant proposal for a study to assess HPV vaccination coverage and associating factors among transgender men in 3 clinics in Los Angeles County. The project will be a two-year descriptive correlational study involving enrollment of 270 transgender men from 3 clinical facilities in Los Angeles County providing STD care to LGBT populations between the ages of 18-26.

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.